|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 9 (November 1), 1998:
pp. 3025-3034
RAPID COMMUNICATION
The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3
and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid
Transcripts
Marta Chesi,
Elena Nardini,
Robert S.C. Lim,
Kerrington D. Smith,
W. Michael Kuehl, and
P. Leif Bergsagel
From the Department of Medicine, the Division of Hematology and
Oncology, Weill Medical College of Cornell University, New York, NY;
and the Genetics Department, Medicine Branch, National Cancer
Institute, Bethesda, MD.
Previously we reported that a karyotypically silent
t(4;14)(p16.3;q32.3) translocation is present in about 25% of multiple myeloma (MM) tumors, and causes overexpression of FGFR3, which is 50 to
100 kb telomeric to the 4p16 breakpoints. Frequent FGFR3 kinase
activating mutations in MM with t(4;14) translocations substantiate an
oncogenic role for FGFR3. We now report that the 4p16 breakpoints occur
telomeric to and within the 5 introns of a novel gene,
MMSET (Multiple Myeloma SET
domain). In normal tissues, MMSET has a complex pattern of expression
with a short form (647 amino acids [aa]) containing an HMG box and
hath region, and an alternatively spliced long form (1365 aa)
containing the HMG box and hath region plus 4 PHD fingers and a
SET domain. Although t(4;14) translocation results in IgH/MMSET hybrid
transcripts, overexpression of MMSET also occurs from endogenous
promoters on 4p16. Given the homology to HRX/MLL1/ALL1
at 11q23 that is dysregulated by translocations in acute leukemia, we
hypothesize that dysregulation of MMSET contributes to
neoplastic transformation in MM with t(4;14) translocation. This is the
first example of an IgH translocation that simultaneously dysregulates
two genes with oncogenic potential: FGFR3 on der(14) and
MMSET on der(4).
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Li, P. Trojer, C.-F. Xu, P. Cheung, A. Kuo, W. J. Drury III, Q. Qiao, T. A. Neubert, R.-M. Xu, O. Gozani, et al.
The Target of the NSD Family of Histone Lysine Methyltransferases Depends on the Nature of the Substrate
J. Biol. Chem.,
December 4, 2009;
284(49):
34283 - 34295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kang, S. Elf, S. Dong, T. Hitosugi, K. Lythgoe, A. Guo, H. Ruan, S. Lonial, H. J. Khoury, I. R. Williams, et al.
Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation
Mol. Cell. Biol.,
April 15, 2009;
29(8):
2105 - 2117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L.R. Brito, B. Walker, M. Jenner, N. J. Dickens, N. J.M. Brown, F. M. Ross, A. Avramidou, J. A.E. Irving, D. Gonzalez, F. E. Davies, et al.
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Haematologica,
January 1, 2009;
94(1):
78 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Yeung and H Chang
Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma
J. Clin. Pathol.,
July 1, 2008;
61(7):
832 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. J. Guikema, E. Schuuring, and P. M. Kluin
Structure and Consequences of IGH Switch Breakpoints in Burkitt Lymphoma
J Natl Cancer Inst Monographs,
July 1, 2008;
2008(39):
32 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Marango, M. Shimoyama, H. Nishio, J. A. Meyer, D.-J. Min, A. Sirulnik, Y. Martinez-Martinez, M. Chesi, P. L. Bergsagel, M.-M. Zhou, et al.
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Blood,
March 15, 2008;
111(6):
3145 - 3154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lauring, A. M. Abukhdeir, H. Konishi, J. P. Garay, J. P. Gustin, Q. Wang, R. J. Arceci, W. Matsui, and B. H. Park
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity
Blood,
January 15, 2008;
111(2):
856 - 864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gonzalez, M. van der Burg, R. Garcia-Sanz, J. A. Fenton, A. W. Langerak, M. Gonzalez, J. J. M. van Dongen, J. F. San Miguel, and G. J. Morgan
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma
Blood,
November 1, 2007;
110(9):
3112 - 3121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. VanDijken, G. V. Kaigala, J. Lauzon, A. Atrazhev, S. Adamia, B. J. Taylor, T. Reiman, A. R. Belch, C. J. Backhouse, and L. M. Pilarski
Microfluidic Chips for Detecting the t(4;14) Translocation and Monitoring Disease during Treatment Using Reverse Transcriptase-Polymerase Chain Reaction Analysis of IgH-MMSET Hybrid Transcripts
J. Mol. Diagn.,
July 1, 2007;
9(3):
358 - 367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1886 - 1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Miremadi, M. Z. Oestergaard, P. D.P. Pharoah, and C. Caldas
Cancer genetics of epigenetic genes
Hum. Mol. Genet.,
April 15, 2007;
16(R1):
R28 - R49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al.
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Blood,
April 15, 2007;
109(8):
3489 - 3495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Masih-Khan, S. Trudel, C. Heise, Z. Li, J. Paterson, V. Nadeem, E. Wei, D. Roodman, J. O. Claudio, P. L. Bergsagel, et al.
MIP-1{alpha} (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
Blood,
November 15, 2006;
108(10):
3465 - 3471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ren, D. Raina, W. Chen, G. Li, L. Huang, and D. Kufe
MUC1 Oncoprotein Functions in Activation of Fibroblast Growth Factor Receptor Signaling
Mol. Cancer Res.,
November 1, 2006;
4(11):
873 - 883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Xin, T. J. Abrams, P. W. Hollenbach, K. G. Rendahl, Y. Tang, Y. A. Oei, M. G. Embry, D. E. Swinarski, E. N. Garrett, N. K. Pryer, et al.
CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3-Expressing Orthotopic Multiple Myeloma Model in Mice.
Clin. Cancer Res.,
August 15, 2006;
12(16):
4908 - 4915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, A. K. Stewart, E. Rom, E. Wei, Z. H. Li, S. Kotzer, I. Chumakov, Y. Singer, H. Chang, S.-B. Liang, et al.
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Blood,
May 15, 2006;
107(10):
4039 - 4046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gertz, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, M. R. Litzow, K. J. Henderson, S. A. Van Wier, G. J. Ahmann, and R. Fonseca
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
Blood,
October 15, 2005;
106(8):
2837 - 2840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Agnelli, S. Bicciato, M. Mattioli, S. Fabris, D. Intini, D. Verdelli, L. Baldini, F. Morabito, V. Callea, L. Lombardi, et al.
Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations
J. Clin. Oncol.,
October 10, 2005;
23(29):
7296 - 7306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Jaksic, S. Trudel, H. Chang, Y. Trieu, X. Qi, J. Mikhael, D. Reece, C. Chen, and A. K. Stewart
Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance
J. Clin. Oncol.,
October 1, 2005;
23(28):
7069 - 7073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Bergsagel and W. M. Kuehl
Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6333 - 6338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Stewart and R. Fonseca
Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
J. Clin. Oncol.,
September 10, 2005;
23(26):
6339 - 6344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Landais, R. Quantin, and E. Rassart
Radiation Leukemia Virus Common Integration at the Kis2 Locus: Simultaneous Overexpression of a Novel Noncoding RNA and of the Proximal Phf6 Gene
J. Virol.,
September 1, 2005;
79(17):
11443 - 11456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, I. R. Williams, B. H. Lee, N. Duclos, B. J. P. Huntly, D. J. Donoghue, and D. G. Gilliland
Constitutively activated FGFR3 mutants signal through PLC{gamma}-dependent and -independent pathways for hematopoietic transformation
Blood,
July 1, 2005;
106(1):
328 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chang, A. K. Stewart, X. Y. Qi, Z. H. Li, Q. L. Yi, and S. Trudel
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
Blood,
July 1, 2005;
106(1):
353 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Melnick, K. Adelson, and J. D. Licht
The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?
J. Clin. Oncol.,
June 10, 2005;
23(17):
3957 - 3970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Keats, C. A. Maxwell, B. J. Taylor, M. J. Hendzel, M. Chesi, P. L. Bergsagel, L. M. Larratt, M. J. Mant, T. Reiman, A. R. Belch, et al.
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
Blood,
May 15, 2005;
105(10):
4060 - 4069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, Z. H. Li, E. Wei, M. Wiesmann, H. Chang, C. Chen, D. Reece, C. Heise, and A. K. Stewart
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
Blood,
April 1, 2005;
105(7):
2941 - 2948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Dring, F. E. Davies, J. A. L. Fenton, P. L. Roddam, K. Scott, D. Gonzalez, S. Rollinson, A. C. Rawstron, K. S. Rees-Unwin, C. Li, et al.
A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma
Clin. Cancer Res.,
September 1, 2004;
10(17):
5692 - 5701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Maxwell, E. Rasmussen, F. Zhan, J. J. Keats, S. Adamia, E. Strachan, M. Crainie, R. Walker, A. R. Belch, L. M. Pilarski, et al.
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma
Blood,
August 15, 2004;
104(4):
1151 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood,
August 1, 2004;
104(3):
607 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Nielsen, P. Jorgensen, T. Lerouge, M. Cervino, P. Chambon, and R. Losson
Nizp1, a Novel Multitype Zinc Finger Protein That Interacts with the NSD1 Histone Lysine Methyltransferase through a Unique C2HR Motif
Mol. Cell. Biol.,
June 15, 2004;
24(12):
5184 - 5196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Magrangeas, M.-L. Cormier, G. Descamps, N. Gouy, L. Lode, M.-P. Mellerin, J.-L. Harousseau, R. Bataille, S. Minvielle, and H. Avet-Loiseau
Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level
Blood,
May 15, 2004;
103(10):
3869 - 3875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, S. Ely, Y. Farooqi, M. Affer, D. F. Robbiani, M. Chesi, and P. L. Bergsagel
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
Blood,
May 1, 2004;
103(9):
3521 - 3528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Soverini, M. Cavo, C. Cellini, C. Terragna, E. Zamagni, D. Ruggeri, N. Testoni, P. Tosi, A. de Vivo, M. Amabile, et al.
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
Blood,
September 1, 2003;
102(5):
1588 - 1594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Keats, T. Reiman, C. A. Maxwell, B. J. Taylor, L. M. Larratt, M. J. Mant, A. R. Belch, and L. M. Pilarski
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
Blood,
February 15, 2003;
101(4):
1520 - 1529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Claudio, E. Masih-Khan, H. Tang, J. Goncalves, M. Voralia, Z. H. Li, V. Nadeem, E. Cukerman, O. Francisco-Pabalan, C. C. Liew, et al.
A molecular compendium of genes expressed in multiple myeloma
Blood,
August 28, 2002;
100(6):
2175 - 2186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, R. J. Bailey, G. J. Ahmann, S. V. Rajkumar, J. D. Hoyer, J. A. Lust, R. A. Kyle, M. A. Gertz, P. R. Greipp, and G. W. Dewald
Genomic abnormalities in monoclonal gammopathy of undetermined significance
Blood,
July 30, 2002;
100(4):
1417 - 1424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Fong, L. Bender, W. Wang, and S. Strome
Regulation of the Different Chromatin States of Autosomes and X Chromosomes in the Germ Line of C. elegans
Science,
June 21, 2002;
296(5576):
2235 - 2238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, E. A. Blood, M. M. Oken, R. A. Kyle, G. W. Dewald, R. J. Bailey, S. A. Van Wier, K. J. Henderson, J. D. Hoyer, D. Harrington, et al.
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
Blood,
May 15, 2002;
99(10):
3735 - 3741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rosati, R. La Starza, A. Veronese, A. Aventin, C. Schwienbacher, T. Vallespi, M. Negrini, M. F. Martelli, and C. Mecucci
NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15)
Blood,
May 15, 2002;
99(10):
3857 - 3860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Reiman, K. Seeberger, B. J. Taylor, A. J. Szczepek, J. Hanson, M. J. Mant, R. W. Coupland, A. R. Belch, and L. M. Pilarski
Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone
Blood,
November 1, 2001;
98(9):
2791 - 2799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Hayman, R. J. Bailey, S. M. Jalal, G. J. Ahmann, A. Dispenzieri, M. A. Gertz, P. R. Greipp, R. A. Kyle, M. Q. Lacy, S. V. Rajkumar, et al.
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis
Blood,
October 1, 2001;
98(7):
2266 - 2268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, M. M. Oken, and P. R. Greipp
The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance
Blood,
August 15, 2001;
98(4):
1271 - 1272.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy Jr, A. Gabrea, Y. Qi, L. Brents, F. Zhan, E. Tian, J. Sawyer, B. Barlogie, P. L. Bergsagel, and M. Kuehl
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma
Blood,
July 1, 2001;
98(1):
217 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Perfetti, A. M. L. Coluccia, D. Intini, U. Malgeri, M. C. Vignarelli, S. Casarini, G. Merlini, and A. Neri
Translocation t(4;14)(p16.3;q32) Is a Recurrent Genetic Lesion in Primary Amyloidosis
Am. J. Pathol.,
May 1, 2001;
158(5):
1599 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Li, Y. X. Zhu, E. E. Plowright, P. L. Bergsagel, M. Chesi, B. Patterson, T. S. Hawley, R. G. Hawley, and A. K. Stewart
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells
Blood,
April 15, 2001;
97(8):
2413 - 2419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chesi, L. A. Brents, S. A. Ely, C. Bais, D. F. Robbiani, E. A. Mesri, W. M. Kuehl, and P. L. Bergsagel
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
Blood,
February 1, 2001;
97(3):
729 - 736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Ho, R. D. Brown, G. J. Pelka, A. Basten, J. Gibson, and D. E. Joshua
Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival
Blood,
January 15, 2001;
97(2):
490 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Garlisi, A. S. Uss, H. Xiao, F. Tian, K. E. Sheridan, L. Wang, M. Motasim Billah, R. W. Egan, K. S. Stranick, and S. P. Umland
A Unique mRNA Initiated within a Middle Intron of WHSC1/MMSET Encodes a DNA Binding Protein That Suppresses Human IL-5 Transcription
Am. J. Respir. Cell Mol. Biol.,
January 1, 2001;
24(1):
90 - 98.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau
Multiple Myeloma
Hematology,
January 1, 2001;
2001(1):
157 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Malgeri, L. Baldini, V. Perfetti, S. Fabris, M. C. Vignarelli, G. Colombo, V. Lotti, S. Compasso, S. Bogni, L. Lombardi, et al.
Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Reverse Transcription-Polymerase Chain Reaction Analysis of IGH-MMSET Fusion Transcripts
Cancer Res.,
August 1, 2000;
60(15):
4058 - 4061.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. G. Willis and M. J. S. Dyer
The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies
Blood,
August 1, 2000;
96(3):
808 - 822.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Pruneri, S. Fabris, L. Baldini, N. Carboni, S. Zagano, M. A. Colombi, G. Ciceri, L. Lombardi, M. Rocchi, R. Buffa, et al.
Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14)
Am. J. Pathol.,
May 1, 2000;
156(5):
1505 - 1513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Garcia, M. Salanoubat, N. Choisne, and A. Tissier
An ATM homologue from Arabidopsis thaliana: complete genomic organisation and expression analysis
Nucleic Acids Res.,
April 15, 2000;
28(8):
1692 - 1699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. G. Janssen, J.-W. Vaandrager, T. Heuser, A. Jauch, P. M. Kluin, E. Geelen, P. L. Bergsagel, W. M. Kuehl, H. G. Drexler, T. Otsuki, et al.
Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32)
Blood,
April 15, 2000;
95(8):
2691 - 2698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Joos, M. Küpper, S. Ohl, F. von Bonin, G. Mechtersheimer, M. Bentz, P. Marynen, P. Möller, M. Pfreundschuh, L. Trümper, et al.
Genomic Imbalances Including Amplification of the Tyrosine Kinase Gene JAK2 in CD30+ Hodgkin Cells
Cancer Res.,
February 1, 2000;
60(3):
549 - 552.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. E. Plowright, Z. Li, P. L. Bergsagel, M. Chesi, D. L. Barber, D. R. Branch, R. G. Hawley, and A. K. Stewart
Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis
Blood,
February 1, 2000;
95(3):
992 - 998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Macintyre, D. Willerford, and S. W. Morris
Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma
Hematology,
January 1, 2000;
2000(1):
180 - 204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Bergsagel, O. Wong, P. L. Bergsagel, R. Alexanian, K. Anderson, R. A. Kyle, and G. K. Raabe
Benzene and Multiple Myeloma: Appraisal of the Scientific Evidence
Blood,
August 15, 1999;
94(4):
1174 - 1182.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Finelli, S. Fabris, S. Zagano, L. Baldini, D. Intini, L. Nobili, L. Lombardi, A. T. Maiolo, and A. Neri
Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization
Blood,
July 15, 1999;
94(2):
724 - 732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
